ProQR Announces R&D Day in New York on June 15

Key updates:

• ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ET
• Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB)
• An update on the innovation/discovery pipeline including programs for Usher syndrome and other DEB mutations
• An introduction to ProQR’s novel RNA editing platform technology called Axiomer

LEIDEN, the Netherlands, May 09, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced a Research & Development Day for investors hosted by the Company’s management team and several key opinion leaders. The event will also be webcast.

The R&D Day will feature presentations by ProQR management on the progress on its pipeline, including a review and introduction of several near- and medium term value drivers. In addition, several leading opinion leaders will discuss the state of the art in research and development on critical areas of the company’s pipeline including CF, inherited blindness, debilitating skin diseases and RNA technologies.

“Following a significant effort to build a diversified product portfolio over the last 5 years, we now have a pipeline that includes two clinical programs, one pre-clinical program and two programs ready to enter development,” said Daniel de Boer, CEO of ProQR. “We’re looking forward to provide an update on the development programs and shine some light on the promising pipeline of discovery programs and a novel RNA editing technology.”

“Over the last several decades the RNA space has matured significantly. With our management and scientific resources we believe we are well positioned to unlock the field’s substantial potential,” said Gerard Platenburg, Chief Innovation Officer at ProQR. “We apply the use of RNA based therapeutics with the goal to make an impact for patients with several severe genetic diseases. Our scientific efforts have also led to a novel proprietary RNA editing platform, called Axiomer, which in our view is the next step in RNA therapeutics, on which we will elaborate at the R&D day.”

R&D Day Event details

On Thursday, June 15, 2017 ProQR will host an R&D day in New York, NY from 8:00am to 1:00pm ET.  Please email Ronen Abergel [email protected] to receive more information and to reserve a seat.

Webcast

The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 90 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of our RNA technology, our innovation programs and pipeline, our discovery efforts and capabilities and our R&D day. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]